TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05017155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexiletine
Description: Mexiletine is a sodium channel blocker shown to be effective in reducing myotonia in a multi-centre randomised trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexiletine
Description: Mexiletine is a sodium channel blocker shown to be effective in reducing myotonia in a multi-centre randomised trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine 25Mg Oral Tablet, Extended Release
Description: Lamotrigine is an alternative sodium channel blocker that has been shown to be effective in one randomised controlled trial. It is currently used as a licensed medication for other neurological conditions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine 25Mg Oral Tablet, Extended Release
Description: Lamotrigine is an alternative sodium channel blocker that has been shown to be effective in one randomised controlled trial. It is currently used as a licensed medication for other neurological conditions.
Study: NCT06231121

Intervention type: DRUG
Intervention: Faricimab
Description: The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
Study: NCT04863716

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fentanyl patient control device
Description: 24-hour fentanyl consumption will be recorded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fentanyl patient control device
Description: 24-hour fentanyl consumption will be recorded.
Study: NCT04677569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Oral tablet
Study: NCT05829057

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous injection of P-IL-2
Description: Ia :Single dose intravenous injection of P-IL-2；

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P-IL-2 plus Anti-PD-1 Monoclonal Antibody
Description: Ib：P-IL-2 plus Anti-PD-1 Monoclonal Antibody；
Study: NCT05221190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single buccal infiltration
Description: injecting local anaesthetic solution into the soft tissues of the buccal sulcus adjacent to the target tooth.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior alveolar nerve block
Description: Injection of local anesthetic solution into the pterygomandibular space to access the inferior alveolar nerve before it enters the mandible.
Study: NCT04677569

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethambutol
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ELC (matching placebo for ALIS)
Description: Inhalation via nebulization over approximately 6 to 15 minutes
Study: NCT05355818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib
Description: Cream for topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream vehicle
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active medical ingredient.
Study: NCT06392841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: Medical castration per ADT with GnRH agonist or antagonist (or surgical castration per orchiectomy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: Medical castration per ADT with GnRH agonist or antagonist (or surgical castration per orchiectomy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: Medical castration per ADT with GnRH agonist or antagonist (or surgical castration per orchiectomy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib/Abiraterone Acetate DAT
Description: Niraparib 200 mg/ Abiraterone acetate 1000 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib/Abiraterone Acetate DAT
Description: Niraparib 200 mg/ Abiraterone acetate 1000 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib/Abiraterone Acetate DAT
Description: Niraparib 200 mg/ Abiraterone acetate 1000 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg orally
Study: NCT05861271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine，Pyrotinib
Description: Pyrotinib and Capecitabine for half a year
Study: NCT05420740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobika OPEP
Description: Subjects given Aerobika OEP to assess changes in small airway disease parameter , CAT Score , 6 minute walking test and exacerbation
Study: NCT05285449

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) powder formulation
Description: 30 mg CBD in the form of 300 mg of 10% CBD isolate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Cannabidiol (CBD) powder formulation
Description: Matching Placebo
Study: NCT05539508

Intervention type: BEHAVIORAL
Intervention: Psychophysical evaluation
Description: All participants will be required to perform a short experiment on a computer (15 minutes) where they will look at different photographs of scenes of different luminance and spatial frequencies. They will have to perform various tasks on these images using the keys on the keyboard.

Intervention type: BEHAVIORAL
Intervention: Psychophysical evaluation
Description: All participants will be required to perform a short experiment on a computer (15 minutes) where they will look at different photographs of scenes of different luminance and spatial frequencies. They will have to perform various tasks on these images using the keys on the keyboard.
Study: NCT06145074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration.
Study: NCT05426525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Participants will take 10mg empagliflozin per day for 2 weeks. Absent contraindications, dosing will be increased to 25 mg empagliflozin per day for the next 11 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin-Placebo
Description: Participants will take 1 multivitamin per day for 13 weeks.
Study: NCT05314725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: 10 days of SGLT2 inhibitor after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 days of placebo after surgery
Study: NCT05855187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bravamax 200 mg (Modafinil)
Description: Test drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigil 200 mg (Modafinil)
Description: Reference drug
Study: NCT06739395

Intervention type: DRUG
Group type: OTHER
Intervention: Target Gene
Description: Granting CFDA or FDA approved drugs(off-label approved drugs) based on specific molecular characteristics.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
Study: NCT06739603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmaceutical analysis
Description: pharmaceutical analysis
Study: NCT06738420

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ABB S3
Description: Postbiotic ABB S3 for suspension into Nutritional supplementation with Medical Nutrition Formula for the management of gastrointestinal symptoms secondary to enteral nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ABB C22
Description: Oral Rehydration Solution containing postbiotics ABB C22 for the management of diarrhoea signs of dehydration
Study: NCT06392841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 IV
Study: NCT05443750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Behavioral Economic Alcohol Intervention
Description: The intervention combines an alcohol brief motivational intervention (US-THRIVE \[Tertiary Health Research Intervention via Email\]) with the Substance-Free Activity Session (SFAS), shown to reduce drinking and related negative consequences by increasing future orientation and engagement in pro-social alternatives to drinking. The intervention will be delivered using a web-based platform appropriate for the young adult target population whose social networks operate through such communications.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Participants view web-based health educational material about alcohol, sleep, and nutrition of a similar length and style to the experimental intervention materials.
Study: NCT05217108

Intervention type: DEVICE
Group type: OTHER
Intervention: FitBit
Description: All participants in each study group will receive a Fitbit. Participants will be asked to wear a Fitbit every day for 8 weeks to record the number of steps you take
Study: NCT06738420

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for suspension into Nutritional supplementation with Medical Nutrition Formula for the management of gastrointestinal symptoms secondary to enteral nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Rehydration Solution containing placebo for the management of diarrhoea signs of dehydration
Study: NCT06737003

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal high frequency oscillatory ventilation
Description: NHFOV was administered using the SLE 6000 device manufactured by Wipro GE Healthcare Private Limited in Bengaluru, Karnataka. The initial amplitude was set at 25 cm H2O and adjusted to a maximum of 35 cm H2O based on clinical response. The frequency was set at 12 Hz. The mean airway pressure (MAP) was initiated at 6 cmH2O and titrated up to 10 cmH2O based on clinical assessment. The I:E ratio was maintained between 1:1 to 1:2 in cases of air trapping, using nasal prongs •

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vapotherm Group
Description: The Hi-VNI Vapotherm was administered using the Vapotherm device, manufactured by Vapotherm, INC, USA. Initially, the flow rate was set at 4 L/min and adjusted accordingly to achieve the desired clinical outcome, with a maximum flow rate of 8 L/min when necessary. The temperature was maintained at 36-37°C, and the FiO2 was adjusted as required to attain the target SpO2 range of 90% to 94%، using soft nasal cannula interface

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal CPAP Group
Description: CPAP therapy was administered using the MEDIN CNO device, developed by medin Medical Innovations GmbH in Olching, Germany. The initial pressure was set at 5 cmH2O and adjusted accordingly to achieve the desired clinical outcome, with a maximum pressure of 8 cmH2O. This approach aimed to maintain the target oxygen saturation (SpO2) levels between 90% and 94%، using bi-nasal with midline prongs
Study: NCT06740760

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Genetic counselling
Description: Behavioral: genetic counselling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Leaflet
Description: Genetic information as a form of a leaflet
Study: NCT06738862

Intervention type: OTHER
Intervention: PET
Description: \[18F\] - FD17 PET/MRI imaging

Intervention type: OTHER
Intervention: PET
Description: \[18F\] - FD17 PET/MRI imaging

Intervention type: OTHER
Intervention: PET
Description: \[18F\] - FD17 PET/MRI imaging

Intervention type: OTHER
Intervention: PET
Description: \[18F\] - FD17 PET/MRI imaging
Study: NCT06739681

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Intervention
Description: These routine exercises used in archery training will be applied to all participants. Exercise sessions will be planned 2 days a week, every other day, for 8 weeks. It will progress progressively according to the athlete's tolerance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Intervention
Description: These routine exercises used in archery training will be applied to all participants. Exercise sessions will be planned 2 days a week, every other day, for 8 weeks. It will progress progressively according to the athlete's tolerance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mental Imagery Intervention
Description: Mental Imagination will be done with Recording Audio. An audio recording will last 5 minutes. The audio recording will be listened to 3 times in one session. The total visualization session will last 15 minutes in a dark and quiet room.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing Exercise Intervention
Description: Participants participating in Pranayama training will practice in a comfortable position in a quiet room at a temperature of 25 ± 2°C. The slow pranayama technique chosen is alternate nasal breathing (Nadishodhana Pranayama).
Study: NCT06738641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pro2col Health
Description: The Pro2col Health application is a smartphone application that provides users with health behavior guidance, personalized feedback, and assessments designed to estimate their current healthspan and biological age.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive subject-facing materials depicting current general activity recommendations as published by the American Heart Association (AHA) and current dietary guidelines provided by the United States Department of Agriculture (USDA).
Study: NCT06739070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric
Description: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenics
Description: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump

Intervention type: OTHER
Group type: OTHER
Intervention: Control group (no intervention)
Description: In control group no intervention would be given. Initial test would be performed at 4th and 8th week and then results would be compared with experimental group.
Study: NCT04831307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-HTK03149 PET/CT
Description: 200 MBq/m2 of body surface area, with a 200 MBq minimum adult administered activity will be injected intravenously prior to perform the PET/CT
Study: NCT06413186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Uteratonic administration
Description: Administer IV 10 IU oxytocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uteratonic administration
Description: Administer IV 10 IU oxytocin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cord clamping
Description: delayed cord clamping

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cord clamping
Description: delayed cord clamping

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: delivery of the placenta
Description: Applying controlled core traction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: delivery of the placenta
Description: Applying controlled core traction
Study: NCT05381961

Intervention type: DEVICE
Intervention: Bioimpedance spectroscopy (BIS) measurement, SOZO device
Description: All patients enrolled in this study will undergo BIS measurement before and after 12 hemodialysis sessions (pre-dialysis and post-dialysis BIS measurements for each session). Measurements are not provided to treating physicians and are not used to guide clinical decisions; i.e., BIS measurements are collected for observational purposes only.

Intervention type: DEVICE
Intervention: Bioimpedance spectroscopy (BIS) measurement, SOZO device
Description: All patients enrolled in this study will undergo BIS measurement before and after 12 hemodialysis sessions (pre-dialysis and post-dialysis BIS measurements for each session). Measurements are not provided to treating physicians and are not used to guide clinical decisions; i.e., BIS measurements are collected for observational purposes only.
Study: NCT06737458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine + Dexmedetomidine
Description: Patients received serratus anterior plane block on the operated side with bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine + Dexmedetomidine
Description: Patients received erector spinae plane block at T5 on the operated side and will receive bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.
Study: NCT06740812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: Fosaprepitant 150mg IV administered over 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Metoclopramide 10mg IV administered over 15 minutes
Study: NCT06739954

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mulligan's Two Leg Rotation technique
Description: The participants will undergo Mulligan's Two Leg Rotation technique, performing 10 repetitions with a 30-second hold for each repeat. There will be a 1-minute rest period between each stretch. The therapist positions themselves on the affected side of the supine patient lying on the treatment table and holds onto the side of the table with their hand on the opposite side. Both legs will be bent so that the feet are raised from the plinth. Maintaining the subject's shoulders on the bed, he gradually moves the subject's legs to the side, considering the restricted flexibility of the hamstring muscles. Once the patient reaches their maximum, the therapist applies extra pressure to sustain the posture for 30 seconds. Then, the legs are lowered to the plinth. A 1-minute interval was provided between each stretch, and the stretches were performed for a total of 10 repetitions. The identical technique is performed on the opposite side to address insufficient flexibility in the hamstrings.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: The DN technique, based on previous research, involved slowly inserting and removing the needle in the muscle or tendon to elicit a specific response. This response could be a local twitch, a dull ache, a feeling of heaviness or distension, or the reproduction of the participant's symptoms. The needle is manipulated in and out of the targeted tissue five times every five minutes for a total of fifteen minutes. After the treatment, sterile gauze is applied and pressed on the DN site, and sterile non-stick pads are used to cover the treated areas. The number of needles used varied depending on the participant's condition. The knee muscles that will be included in the dry needling intervention are the Quadriceps and Hamstrings .
Study: NCT06741215

Intervention type: OTHER
Intervention: Hand Rehabilitation
Description: Passive mobilization exercises were initiated for these patients in the first postoperative week.~Flexor tendon repair patients were immobilized for 3-4 weeks postoperatively. During this period, passive mobilization exercises were with controlled movement. After removing the splint in the third or fourth week, tendon-gliding exercises were initiated, followed by isolated tendon-gliding exercises in the fifth week. Electrotherapy was started in the sixth week (5 days a week, for 15 sessions).~For extensor tendon repair patients, immobilization lasting 3-6 weeks was applied based on the injury level. During immobilization, passive range of motion (ROM) exercises were performed for adjacent joints while the hand remained in the splint. After splint removal, active and passive ROM exercises, and tendon-gliding exercises with gradually increasing intensity were started according to the injury level. Electrotherapy was started in in the sixth week.

Intervention type: OTHER
Intervention: Hand Rehabilitation
Description: Passive mobilization exercises were initiated for these patients in the first postoperative week.~Flexor tendon repair patients were immobilized for 3-4 weeks postoperatively. During this period, passive mobilization exercises were with controlled movement. After removing the splint in the third or fourth week, tendon-gliding exercises were initiated, followed by isolated tendon-gliding exercises in the fifth week. Electrotherapy was started in the sixth week (5 days a week, for 15 sessions).~For extensor tendon repair patients, immobilization lasting 3-6 weeks was applied based on the injury level. During immobilization, passive range of motion (ROM) exercises were performed for adjacent joints while the hand remained in the splint. After splint removal, active and passive ROM exercises, and tendon-gliding exercises with gradually increasing intensity were started according to the injury level. Electrotherapy was started in in the sixth week.
Study: NCT06740786

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin Treatment Group
Description: This group of patients will receive dapagliflozin treatment after undergoing atrial fibrillation catheter ablation.~Treatment regimen: Dapagliflozin will be administered orally once daily at the recommended dose (e.g., 10 mg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin Treatment Group
Description: This group of patients will receive dapagliflozin treatment after undergoing atrial fibrillation catheter ablation.~Treatment regimen: Dapagliflozin will be administered orally once daily at the recommended dose (e.g., 10 mg/day).